Access the full text.
Sign up today, get DeepDyve free for 14 days.
Andrew Williams, Gregorio Valdez, V. Moresi, X. Qi, John McAnally, J. Elliott, R. Bassel-Duby, J. Sanes, E. Olson (2009)
MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in MiceScience, 326
Zeljka Gadze, S. Hajnsek, S. Basic, D. Sporiš, G. Pavliša, S. Nanković (2009)
Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case reportBMC Neurology, 9
J. Leavitt (2009)
Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 PatientsYearbook of Neurology and Neurosurgery, 2009
A. Jacob, M. Matiello, B. Weinshenker, D. Wingerchuk, C. Lucchinetti, E. Shuster, J. Carter, B. Keegan, O. Kantarci, S. Pittock (2009)
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.Archives of neurology, 66 9
J. Perlmutter, J. Mink (2006)
Deep brain stimulation.Annual review of neuroscience, 29
K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, Fusheng Yang, G. Cole (1996)
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic MiceScience, 274
Elsone L, Townsend T, Mutch K
Neuropathic pruritus (itch) in neuromyelitis optica [published online August 30, 2012].Mult Scler
L. Ittner, T. Fath, Y. Ke, Mian Bi, Janet Eersel, Kong Li, P. Gunning, J. Götz (2008)
Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementiaProceedings of the National Academy of Sciences, 105
S. Nishiyama, T. Ito, T. Misu, Toshiyuki Takahashi, A. Kikuchi, N. Suzuki, K. Jin, M. Aoki, K. Fujihara, Y. Itoyama (2009)
A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onsetNeurology, 72
G. Bates, L. Mangiarini, A. Mahal, S. Davies (1999)
Transgenic models of Huntington's disease.Human molecular genetics, 6 10
R. Mandler, W. Ahmed, J. Dencoff (1998)
Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprineNeurology, 51
R. Govindarajan, E. Salgado (2012)
Is it too early to predict the failure of natalizumab in NMO?Archives of neurology, 69 8
L.D. Bond, G.C. Keough (2003)
Neurogenic pruritus: a case of pruritus induced by transverse myelitisBritish Journal of Dermatology, 149
B. Carlson (2012)
Diversity Matters The Importance of Comparative Studies and the Potential for Synergy Between Neuroscience and Evolutionary Biology
C. Costanzi, M. Matiello, C. Lucchinetti, B. Weinshenker, S. Pittock, Jay Mandrekar, P. Thapa, A. McKeon (2011)
Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis opticaNeurology, 77
M. Mealy, D. Wingerchuk, B. Greenberg, M. Levy (2012)
Epidemiology of neuromyelitis optica in the United States: a multicenter analysis.Archives of neurology, 69 9
We read with interest the article by Mealy at al1 on the clinicopathologic spectrum of neuromyelitis optica (NMO)/NMO spectrum disorder. We have the following additional comments on the NMO spectrum: Recurrent Conus Myeloradiculitis as a Presentation of NMO Spectrum Disorder A 42-year old woman presented with sudden-onset urinary retention that rapidly progressed to a flaccid paraplegia. Results of imaging studies were negative initially; repeat magnetic resonance imaging 5 days from symptom onset revealed conus myeloradiculitis. Results from extensive testing, including spinal angiogram as well as testing for NMO antibodies and visual evoked potentials, were negative. Results from repeat NMO antibody testing 1 year from the initial symptom onset were positive. Few reports have described conus involvement with NMO2; root involvement with NMO is even more rarely described. There are no cases in the current series where there is conus involvement or root involvement. Intractable Generalized Neuropathic Pruritus as a Heralding Symptom of NMO A 36-year-old woman presented with intractable generalized pruritus for 3 months, after which she developed quadriplegia with bulbar weakness. Cervical spine magnetic resonance imaging showed longitudinally extensive myelopathy from C2 to C5 with no enhancement. Results from tests for visual evoked potentials were normal, while test results for NMO antibodies and anti–Sjögren syndrome antigen A antibodies were positive. Few studies have described generalized pruritus with NMO.3 It would be interesting to know the prevalence of pruritus in NMO in the current study. Is Multiple Sclerosis Immunotherapy Beneficial in Some Patients With NMO? Although reports from previous case series have concluded that multiple sclerosis immunotherapy, including interferon and natalizumab, might not be beneficial in NMO, we reported a case where the patient initially diagnosed as having multiple sclerosis remained stable while taking interferons and natalizumab for many years and was eventually diagnosed as having NMO.4 It is unclear whether there is a subgroup of patients with NMO who might benefit from some of the multiple sclerosis immunomodulators. In conclusion, we agree with the authors that given the rarity of NMO, having a national registry or even a regional consortium would help answer some of these questions and shed more light on its protean manifestations. Back to top Article Information Correspondence: Dr Govindarajan, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331 (raghav316g@gmail.com). Conflict of Interest Disclosures: None reported. References 1. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176-118022733096PubMedGoogle ScholarCrossref 2. Elsone L, Townsend T, Mutch K, et al. Neuropathic pruritus (itch) in neuromyelitis optica [published online August 30, 2012]. Mult Scler22936333PubMedGoogle Scholar 3. Petelin Gadze Z, Hajnsek S, Basic S, Sporis D, Pavlisa G, Nankovic S. Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case report. BMC Neurol. 2009;9:5619852774PubMedGoogle ScholarCrossref 4. Govindarajan R, Salgado E. Is it too early to predict the failure of natalizumab in NMO? Arch Neurol. 2012;69(8):1085-1086, author reply 108622892674PubMedGoogle Scholar
JAMA Neurology – American Medical Association
Published: Feb 1, 2013
Keywords: neuromyelitis optica
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.